Table 1.
Formulation | Atractylodin (mg) | Acetone (mL) | 12,000 MW PLGA (mg) | 48,000 MW PLGA (mg) | 1% Poloxamer 407 (mL) |
---|---|---|---|---|---|
ALNPs-1 | 1 | 1.5 | 22.5 | - | 15 |
ALNPs-2 | 1 | 1.5 | - | 22.5 | 15 |
Blank NPs-1 | - | 1.5 | 22.5 | - | 15 |
Blank NPs-2 | - | 1.5 | - | 22.5 | 15 |
Formulation | Atractylodin (mg) | Acetone (mL) | 12,000 MW PLGA (mg) | 48,000 MW PLGA (mg) | 1% Poloxamer 407 (mL) |
---|---|---|---|---|---|
ALNPs-1 | 1 | 1.5 | 22.5 | - | 15 |
ALNPs-2 | 1 | 1.5 | - | 22.5 | 15 |
Blank NPs-1 | - | 1.5 | 22.5 | - | 15 |
Blank NPs-2 | - | 1.5 | - | 22.5 | 15 |